Skip to main content
. 2022 Feb 5;27(2):149–164. doi: 10.1007/s12192-022-01257-1

Fig. 5.

Fig. 5

The effects of NRF2 activator SFN on HG and H/R-treated H9c2 cardiomyocytes. *P < 0.05 vs. vehicle group. #P < 0.05 vs. H/R group. &P < 0.05 vs. HG group. P < 0.05 vs. HH/R group. SFN sulforaphane